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Plasma Dexamethasone Levels in Children Given the 
Dexamethasone Suppression Test 
Michael W. Naylor, John F. Greden, and Norman E. Alessi 
To determine whether chi'~dre~ who demonstrate dexamethasone suppression test (DST) 
nonsuppression have l~¢e~ ~ plasma dexamethasone levels than DST suppressors, we 
administered the DST to 73 patients ranging in age fiom 5-14 years. Plasma dexameth- 
asone levels and postdexamethasone cortisol levels were measured at 4:00 PM on day 2. 
We found: (1) DST nonsuppressors had significantly lower plasma dexamethasone levels 
(p < 0.03) than suppressors; similar trends were observed when the population was 
divided into depressed and nondepressed patients; (2) mglm 2 dose of de:~amethasone was 
directly correlated with plasma dexamethasone ( p < 0.003) and inversely correlated with 
postdexamethasone plasma cortisol levels (p < 0.04); and (3) a statistically significant 
inverse correlation between plasma dexamethasone levels and postdexamethasone cortisol 
levels (p < 0.04). Our findings show that plasma dexamethasone levels are important 
in evaluating DST results in psychiatrically disturbed children and suggest that dexa- 
methasone dosage j r use in the DST in children might be better calculated in terms of 
body surface area. 
Introduction 
Plasma dexamethasone levels are an important variable in understanding hypothalamic- 
pituitary-adrenal (HPA) axis dysregulation in psychiatrically disturbed adults. Investi- 
gators have found that depressed adults who are nonsuppressors on the dexamethasone 
suppression test (DST) have significantly lower plasma dexamethasone concentrations 
than depressed patients and control subjects who are DST suppressors (Johnson et al. 
1984; Arana et al. 1984; Maguire et al. 1987). Several explanations have been advanced 
for this observation. Lowy and Meltzer (1987) raised the possibility that bioavailability 
of dexamethasone pla3s ,~ ma~or r~!e in determining DST suppressor status and have 
suggested that simultaneous measurement of plasma dexamethasone and cortisol levels 
are needed to evaluate DST results. Alternatively, Holsboer and associates (1986a and 
b) concluded that the low plasma dexamethasone levels in nonsuppressing adult depres- 
sives were due to accelerated metabolism of dexamethasone rather than impaired bio- 
availability, and suggested that the abnormality of glucocorticoid nactabolism in depres- 
sives with DST nonsuppression is state-dependent. 
Although the plasma dexamethasone variable has not been studied in children, the 
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association between suppressor status and dexamethasone dose has been. In a study of 
97 children aged 3 to 16 years, Doberty and co-workers (1986) found no significant 
difference in the percentage of depressed children who failed to suppress at high, medium, 
or low doses of dexamethasone based on body weight. 
We undertook this study to exan~ine the relationship between plasma dexamethasone 
levels and DST suppressor status in children. We hypothesized that: (1) psychiatrically 
disturbed children with DST nonsuppression would have lower plasma dexamethasone 
levels than DST suppressors regardless of diagnosis; and (2) dexamethasone dosage would 




Seventy-three children (aged 5-14 years) admitted to the Diagnostic and Research Unit 
at the University of Michigan Hospitals were administer~ ~:he dexamethasone suppression 
test (DST), regardless of diagnosis. Exclusion criteria for the DST wen as described by 
Carroll et al. (1981). Demographic data are presemed in Table 1. Major depressive 
disorder was the primary diagnosis in 14 children, dysthymic disorder in 11, adjustment 
disorder with depressed mood in 2, attention deficit disorder with hyperactivity in 11, 
anxiety disorder in 6, conduct disorder in 13, oppositional disorder in 3, schizophrenia 
in 1, adjustment disorder with mixed disorder of mood and conduct in 3, pervasive 
developmental disorder in 3, psychosomatic disorder in 3, ~a0 personality disorder in 2. 
We initially divided the population into DST suppressors and nonsuppressors and 
subsequently subdivided the population into depressed (major depressive disorder and 
dysthymic disorder) and nondepressed (all other diagnoses). The 2 children diagnosed as 
having an adjustment disorder with depiessed mood were assigned to the nondepressed 
group (both were DST suppressors, and analysis of the data with these 2 children cate- 
gorized as depressed did not change the results). 
Diagnostic Procedure 
Each child was rigorously evaluated medically and psychiatrically. Height and weight 
were recorded and body surface area was determined according to the method of Gehan 
ana George (1970). Each patient and his or her family were interviewed by a senior staff 
ps~,,niatrist and a fellow in child psychiatry. Developmental and family history were 
obtained in the initial interview, and academic history was obtained from the child's 
school teacher. Further diagnostic information obtained during the first 2 weeks of hos- 
pitalization included neuropsychologicai e~d psychological testing, milieu observations, 
and reports from the hospital's school. Consensual diagnoses were made after 2 weeks 
of hospitalization based on all available information according to unmodified DSM-HI 
criteria. 
DST Procedure 
The DST was performed within the first week of hospitalization. All patients were 
medication free for at least 2 weeks before having the DST. After we obtained informed 
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cortisol level at 11:00 PM on day 1, then gave each subject dexamethasone. For children 
weighing less than 36 kg, we administered 0.5 mg of dexamethasone as described by 
Poznansld et al. (1982). This dosage was based on the ration'de that the children would 
receive approximately the same dose of dexamethasone on a mg./kg basis that ~n average- 
sized adult would receive. Children weighing 36 kg or more were given 1.0 mg as 
described by Carroll et al. (1981). Thirty-eight children received 0.5 mg of dexamethasone 
whereas 35 received 1.0 mg. Children were observed closely by the nursing staff to 
assure they had taken the dexamethasone tablets. Plasma cortisol, obtained on day 2 at 
4:00 PM, was measured by a competitive protein binding assay with interassay coefficients 
of variation of 7.6, 6.2, and 5.0% at 4.0, 8.0, and 16.0 ILg/dl of cortisol, respectively, 
and intra-assay coefficients of variation of 7.1, 5°8, and 4.7% for the same plasma cortisol 
values. DST nonsuppression was defined as a postdcxamethasone plasma cortisol ~> 5.0 
ttg/dl at 4:00 PM. Concurrent plasma dexamethasone levels were obtained and quantified 
by a radioimmunoassay technique using rabbit antiserum produced against a bovir.c ~er-m 
albumin conjugate of dexamethasone hemisuccinate. The rabbit antiserum for the DST 
assay was provided by Merck Sharpe and Dohme. The sensitivity of the assay is 100 pg/ 
ttl using 100 ttl of plasma and is reliable at plasma dexamethasone levels greater than 
or equal to 10 ng/dl. The assay is highly specific for dexamethasone with no cortisol 
cross-reactivity until the concentration of cortisol exceeds 16-18 ttg/dl. Interassay coef- 
ficients of variation are 6.5 and 5.0% at 109 and 380 ng/dl of dexamethasone, respectively. 
The intra-assay coefficients of variation are 5.5 and 4.8% for the same values. 
Data Analysis 
To test the hypothesis that psychiatrically hospitalized children with DST nonsuppression 
have lower plasma dexamethasone levels than suppressors, we divided the total sample 
into DST suppressors and nonsuppressors and compared plasma dexamethasone levels 
between them using an unpaired, one-tailed t-test. We chose a one-tailed test as we 
postulated a specific directionality to the results and to reduce the likelihood of a Type 
I error, (incorrectly rejecting a tree hypothesis). To determine whether the diagnosis of 
depression was a significant variable, we further subdivided the sample into depres~,ed 
and nondepressed subjects and conducted the same analyses. 
To analyze the data continaously as well as dichotomously, and to test the hypothesis 
that dexamethasone dosage would correlate directly with plasma dexamethasone and 
inversely with postdexamethasone cortisol levels, we calculated Pearson's r correlation 
coefficients using dexamethasone dosage as one variable and plasma dexamethasone L,," 
plasma cortisoi, respectively, as the second variable. Because plasma dexamethasone 
levels and postdexamethasone cortisol levels were not normally distributed, we log trans- 
formed the data before all analyses. For all statistical analyses, we accepted p values of 
<0.05 as significant. 
Results 
Plasma Dexamethasone Levels 
DST nonsuppressors had significantly lower (p < 0.03) plasma dex~nethasone levels 
than suppressors (Table 2). When the total sample was divided according to the pres- 
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Figure l. Mean plasma dexamethasone levels in suppressors (m) and nonsuppressors (Q). *Unpaired, one- 
tailed, t-test; p < 0.03. 
showed a similar trend towards having lower plasma dexamethasone levels; however, 
these findings failed to reach statistical significance (Figure l). Fifteen of the 18 non- 
suppressors received 0.5 mg of dexamethasone (5 with depression and l0 with other 
diagnoses). Of the 3 nonsuppressors given 1.0 mg, 2 were depressed. X2-analysis of 
the data revealed no differences in gender distribution between the various groups, 
suggesting that gender was not a major variable affecting plasma dexamethasone levels 
or DST suppressor status. 
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Table 3. Correlation Among Dexamethasone Dose, Plasma Dexamethasone Levels, and 
Postdexamethasone Plasma Cortisol Levels 
Total sample Nonsuppressors Suppressors 
(n = 73) (n = 18) (n = 55) 
Plasma Plasma Plasma Plasma P lasma Plasma 
dexamethasone cortisol dexamethasone cortisol dexamethasone  cortisol 
Dexamethasone + 0.09 - 0 .04 + 0.18 + 0.31 - 0 .04  + 0.02 
dose (mg/kg)  
Dexamethasone + 0.35 ° - 0.25 b + 0 .40 + 0.40 + 0 .29 b - 0 .19 
dose (mg/m 2) 
Plasma cortisol - 0.25 b - -  + 0 .24 - -  - 0 .58 c 
"p < 0.003. 
~p < o.o4. 
ep < O.OOOL 
Association Between Dexamethasone Dose, Plasma Dexamethasone, and 
Postdexamethasone Plasma Cortisol Levels 
As shown in Table 3, mg/m 2 dose of dexamethasone was directly correlated with plasma 
dexamethasone levels for the total sample (p < 0.003) and for DST suppressors (p < 
0.04), and inversely correlated with 4:00 PM postdexarnethasone plasma cortisol levels 
for the total sample (p < 0.04). There was no correlation between mg/kg dexamethasone 
dose and plasma dexamethasone concentrations or postdexamethasone cortisol levels. We 
found a statistically significant inverse correlation between plasma dexamethasone levels 
and postdexamethasone cortisol levels for the total sample (p < 0.04) and for DST 
suppressors (p < 0.0001). We found no significant correlations between dexamethasone 
dosage and plasma dexamethasone or cortisol concentrations, or between plasma dexa- 
methasone concentrations and postdexamethasone plasma conisol levels in DST nonsup- 
pressors. 
As shown in Tables I and 2, DST nonsuppressors were significantly younger, lighter, 
and smaller, and received less dexamethasone, either absolute or expressed in terms of 
mg/m 2, than suppressors. 
Discussion 
The results of thaw ~tudy support our hypothesis that DST nonsuppression in children is 
associated with low plasma dexamethasone levels when compared with DST suppressors. 
Our hypothesis that dexamethasone dosage is directly correlated with plasma dexameth- 
asone levels and inversely with plasma cortisol levels was also supported. Mg/m 2, but 
not mg/kg, dexamethasone dose was directly correlated with plasma dexamethasc.ne levels 
in the total sample and DST suppressors, and inversely correlated with postdexamethasone 
cortisol concentrations in the total sample. We demonstrated an inverse correlation be- 
tween plasma dexamethasone levels and postdexamethasone plasma cortisol concentra- 
tions for the total sample. Interestingly, however, we found no significant correlation 
among dexamethasone dosage and plasma dexamcthasone or cortisol concentrations, or 
between plasma dexamethasone levels and cortisol concentrations in DST nonsuppressors. 
It is not possible with this study design to address the question of why plasma dex- 
amethasone levels were lower in DST nonsuppressors than in suppressors. Dexamethasone 
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dosage likely accounts for part of the difference. As a group, nonsuppressors received 
significantly smaller mg and mg/m 2 dexamethasone doses than DST suppressors. Age, 
height, weight, and size differences may also account for part of the difference. Non- 
suppressors were younger, smaller, and lighter than suppressors, and it may be that 
younger, smaller children metabolize dexamethasone more rapidly than older, larger ones. 
There is only minimal current support for this hypothesis; however, Richter et al. (1983) 
found that toddlers have lower plasma dexamethasone concentrations than adults after 
administration of equivalent doses of dexamethasone when corrected for weight--which 
offers tentative support. Finally, the lack of significant correlation between plasma dex- 
amethasone levels and postdexamethasone cortisol levels in DST nonsuppressors suggests 
that hypothalamic-pituitary-adrenal axis dysregulation and altered glucocorticoid metab- 
olism may account for the observed difference in plasma dexamethasone levels between 
suppressors and nonsuppressors. 
The findings of this study must be interpreted with caution. There were no normal 
controls for comparison with our patient subgroups. Additionally, patients were not 
randomized to dosage groups nor were they administered both dosages of de×amethasone. 
Finally, severity and duration of the illness were not accounted for in the study design. 
Future studies are necessary to determine the influence of severity and duration of illness, 
age, and size on glucocorticoid metabolism and consequently, dexamethasone suppressor 
status in depressed children. Nevertheless, these data are consistent with those obtained 
from adults. 
This study has several implications for researchers in child psychiatry. The effect of 
dexamethasone dose, and subsequently plasma dexamethasone concentrations, on post- 
dexamethasone plasma cortisol levels and DST suppressor status underscores the need 
for standardization of the DST protocol in children. At least 5 dexamethasone dosage 
strategies have been used by child psychiatric researchers including the modified 0.5 mg 
DST (Poznanski et al. 1982), the standard 1.0 mg DST (Carroll et al. 1981), assignment 
of dexamethasone dosage based on a strict weight cut-off (Jensen and co-workers 1985), 
the use of a 20 ttg/kg dose for all patients (Geller et al. 1983), and assignment of 
dexamethasone dose based on pubertal status (Emslie and co-workers 1987). This lack 
of standardization makes generalization among studies very difficult. The use of a rag/ 
m 2 dose of dexamethasone may be warranted on the basis of our findings and may aid 
in the standardization of the DST in children. Meanwhile, simultaneous measurement of 
plasma dexamethasone and postdexamethasone cortisol levels is indicated to determine 
the effects of various plasma dexamethasone levels on DST suppressor status. 
The authors wish to thank M. Hariharan, Ph.D., for providing plasma dexamethasone assay levels; Cynthia 
Pomerlean, Ph.D., for her editorial assistance; and Nancy Genero, Ph.D., Director of the University of Michigan 
Department of Psychiatry Biometrics Program, for assistance with the statistical analysis. 
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